The Rune Labs software uses the motion sensors built into the
Apple Watch, which can already be used to detect when a person
falls. Rune Labs Chief Executive Brian Pepin told Reuters in an
interview the Apple Watch data will be combined with data from
other sources, including a Medtronic implant that can measure
brain signals.
Rune Labs' goal is for doctors to use the combined data to
decide whether and how to fine-tune the patients' treatment, an
approach called precision medicine. At present, Pepin said, most
doctors have to gather data on a patient's movements by
observing the patient during a short clinical visit, which is
not ideal because Parkinson's symptoms can vary widely over
time.
The Apple Watch will give doctors a continuous stream of
observations over long stretches, Pepin said.
"When you think about the process of getting someone to their
optimal therapy or combination of drugs or devices, or even
whether or not a patient might be a good fit for certain
clinical trial, it's a very hard decision to make when you only
have a little context," Pepin said.
The Rune Labs FDA clearance is the first prominent use of
software tools that Apple released for measuring movement
disorders in 2018.
Last year, a group of scientists at Apple published a study in
the journal Science Translational Medicine showing the device
was effective at monitoring Parkinson's symptoms. After
contacting Apple about the tools, Pepin said "it took about
eight minutes for the team lead to get back to me and say, 'Hey,
perfect, let's explore this.'"
Apple has partnered with a range of other companies to use the
Apple Watch as a health monitoring device, including a deal with
Johnson & Johnson https://www.reuters.com/article/apple-health-jj-idCNL4N2AP0E1
to study whether the watch can be used to help lower stroke
risk.
(Reporting by Stephen Nellis in San Francisco; editing by Diane
Craft)
[© 2022 Thomson Reuters. All rights
reserved.]
Copyright 2022 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|